Get the Stockscreener App
21.37
2.94%
0.61
Mineralys Therapeutics Inc stock is traded at $21.37, with a volume of 647.27K.
It is up +2.94% in the last 24 hours and down -26.08% over the past month.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
See More
Previous Close:
$20.76
Open:
$21.04
24h Volume:
647.27K
Relative Volume:
0.45
Market Cap:
$1.89B
Revenue:
Net Income/Loss:
$-151.78M
P/E Ratio:
-10.38
EPS:
-2.0595
Net Cash Flow:
$-136.42M
1W Performance:
-4.51%
1M Performance:
-26.08%
6M Performance:
-29.75%
1Y Performance:
-50.70%
1-Day Range:
$20.82
$21.83
1-Week Range:
$20.41
$23.68
52-Week Range:
$20.41
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
21.37 | 1.89B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
508.37 | 128.85B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
239.43 | 95.59B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.68 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.36 | 53.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.96 | 42.30B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Initiated | UBS | Neutral |
| Apr-27-26 | Initiated | TD Cowen | Buy |
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 - GlobeNewswire Inc.
After a CEO share sale, 528,621 shares remain with Mineralys Therapeutics (MLYS) chief. - Stock Titan
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 - GlobeNewswire Inc.
A 75,000-share sale is proposed by a Mineralys (MLYS) officer and director. - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com South Africa
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com South Africa
Mineralys Therapeutics director sells $3 million in shares - Investing.com
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
A fund sold Mineralys (MLYS) shares and still holds more than 7.8 million. - Stock Titan
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Mineralys Therapeutics Inc For: 22 September - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com
Fund may sell Mineralys (NASDAQ: MLYS) shares; filing shows the size - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mineralys Therapeutics (MLYS) officer lines up new stock option sale - stocktitan.net
A new employee gets Mineralys stock awards covering 14,880 and 11,160 shares - Stock Titan
Mineralys Therapeutics (MLYS) CCO sells 7,438 shares in pre-set plan - Stock Titan
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics director Karydas sells $85,740 in stock - Investing.com
Mineralys Therapeutics (MLYS) director sells shares under preset plan - stocktitan.net
Mineralys Therapeutics (NASDAQ: MLYS) executive plans new stock option sale after recent $388K trade - stocktitan.net
Mineralys (NASDAQ: MLYS) officer to sell 3,000 shares via options - stocktitan.net
Mineralys (MLYS) officer to sell 7,709 shares - stocktitan.net
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Mineralys Therapeutics grants inducement equity awards covering 52,080 shares to new hires - Bitget
Mineralys at Wells Fargo conference: lorundrostat launch takes shape By Investing.com - Investing.com Canada
MLYS: Lorundrostat nears approval with strong data, broad market prep, and a focus on parity access - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) insider to sell 2,171 shares via cashless option exercise - Stock Titan
Two new hires get four-year stock awards from Mineralys - stocktitan.net
Mineralys Therapeutics Market Sentiment - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Mineralys Therapeutics upgraded to Buy ahead of lorundrostat FDA approval and strong market launch. - Pluang
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS) - Seeking Alpha
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - Stock Titan
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com UK
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan - stocktitan.net
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares - Investing.com
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - stocktitan.net
Mineralys Plunges As Costly Royalty Deal Shocks Wall Street - TipRanks
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management - BioBuzz
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Congleton Jon | Chief Executive Officer |
Sep 30 '26 |
Sale |
25.46 |
75,000 |
1,909,665 |
528,621 |
| Congleton Jon | Officer |
Sep 30 '26 |
Proposed Sale |
25.46 |
75,000 |
1,909,662 |
0 |
| Slingsby Brian Taylor | Director |
Sep 22 '26 |
Sale |
28.81 |
104,320 |
3,005,303 |
7,805,718 |
| CATALYS PACIFIC FUND LP | Director |
Sep 22 '26 |
Proposed Sale |
28.81 |
104,320 |
3,005,303 |
0 |
| Warren Eric | Officer |
Sep 21 '26 |
Proposed Sale |
28.12 |
7,438 |
209,135 |
0 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Option Exercise |
13.24 |
7,438 |
98,479 |
45,838 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Sale |
28.12 |
7,438 |
209,136 |
38,400 |
| Rodman David Malcom | Officer |
Sep 17 '26 |
Proposed Sale |
27.95 |
417 |
11,655 |
0 |
| Karydas Daphne | Officer |
Sep 15 '26 |
Proposed Sale |
28.58 |
3,000 |
85,740 |
0 |
| Karydas Daphne | Director |
Sep 15 '26 |
Option Exercise |
12.02 |
3,000 |
36,060 |
9,200 |
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):